New Insights Into the Far-Reaching Effects of Obesity Medicines

Speaker(s)

• 

  Ted Kyle, RPh, MBA (he/him/his)

  Founder
  ConscienHealth
  Pittsburgh, Pennsylvania, United States

  Disclosure(s): Boehringer Ingelheim: Advisory Committee/Board Member (Ongoing)
  Emerald Lake Safety: Independent Contractor (including contracted research) (Ongoing)
  Novo Nordisk: Advisory Committee/Board Member (Ongoing); Speaker/Speaker's Bureau (Ongoing)
  Nutrisystem: Consultant (Ongoing)
  Roman Health Ventures: Advisory Committee/Board Member (Ongoing)
• GF

  Gary Foster, PhD

  University of Pennsylvania, United States

  Disclosure information not submitted.
• 

  Randy Seeley, PhD (he/him/his)

  Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences
  University of Michigan
  Ann Arbor, Michigan, United States

  Disclosure(s): Amgen: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
  AstraZeneca: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Congruence: Grant/Research Support (Ongoing)
  Coro Bio: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
  Crinetics: Advisory Committee/Board Member (Ongoing)
  Eli Lilly: Consultant (Ongoing); Grant/Research Support (Ongoing)
  Fractyl: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)
  Glyscend: Grant/Research Support (Ongoing)
  Metsera: Consultant (Ongoing)
  Novo Nordisk: Consultant (Terminated, January 1, 2024); Grant/Research Support (Terminated, January 1, 2024)
  Nuanced Health: Advisory Committee/Board Member (Ongoing); Ownership Interest (Ongoing)
  Rewind: Ownership Interest (Ongoing)

Moderator(s)

• LW

  Leah Whigham, PhD, FTOS

  Professor
  Department of Nutritional Sciences
  University of Texas at Austin, United States

  Disclosure information not submitted.

Obesity medicines are transforming the landscape of weight management, with effects extending beyond weight loss to metabolic health, brain function, and consumer behavior. This session will explore the latest insights from neuroscience, clinical practice, and consumer research to provide a comprehensive understanding of how these medications influence biology and behavior. The session will conclude with a panel discussion offering a multidimensional look at the future of obesity treatment and its broader public health implications.

Presentations:

• 10:00 AM – 10:05 AM ET

  Welcome and Introductions - New Insights Into the Far-Reaching Effects of Obesity Medicines
  

  Moderator: Leah Whigham, PhD, FTOS – University of Texas at Austin
• 10:05 AM – 10:25 AM ET

  Insights from Neuroscience
  

  Speaker: Randy Seeley, PhD (he/him/his) – University of Michigan
• 10:25 AM – 10:45 AM ET

  Insights from the Clinic
  

  Speaker: Gary D. Foster, PhD – University of Pennsylvania
• 10:45 AM – 11:05 AM ET

  Insights from Consumer Behavior
  

  Speaker: Ted Kyle, RPh, MBA (he/him/his) – ConscienHealth
• 11:05 AM – 11:30 AM ET

  Panel Discussion - New Insights Into the Far-Reaching Effects of Obesity Medicines
  

  Moderator: Leah Whigham, PhD, FTOS – University of Texas at Austin

  Speaker: Gary D. Foster, PhD – University of Pennsylvania

  Speaker: Ted Kyle, RPh, MBA (he/him/his) – ConscienHealth

  Speaker: Randy Seeley, PhD (he/him/his) – University of Michigan